Microtrast (Barium Sulfate)

Barium sulfate consists of dense, insoluble particles that remain in the GI lumen after ingestion. Their high atomic number absorbs X‑ray photons, creating a bright outline of the gastrointestinal tract on radiographic images, which allows clinicians to assess anatomy and detect abnormalities.

The dose of Microtrast is determined by the prescribing physician based on the specific imaging procedure, patient age, weight and clinical requirements. The healthcare professional will calculate the appropriate volume of the oral suspension for each examination.

Safety data for barium sulfate in pregnancy are limited, and the product should only be used when clearly indicated. It is not known to be excreted in breast milk, but clinicians usually avoid elective use during pregnancy and lactation unless the diagnostic benefit outweighs potential risks.

To place an order, submit an enquiry on the Microtrast product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Microtrast contains barium sulfate, which provides superior radiopacity compared with water‑soluble iodine‑based agents, resulting in clearer images of the GI lumen. However, unlike iodine agents, barium is not suitable for patients with suspected perforation because it can cause peritoneal irritation if it leaks outside the gut.

Microtrast should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the suspension from moisture, direct sunlight and extreme temperatures to maintain its consistency and radiopaque properties.

Microtrast is given orally as a suspension. The prescribed volume is typically mixed with a small amount of water or flavored liquid and ingested by the patient shortly before the radiographic procedure, following the instructions of the radiology team.

Serious risks include aspiration of the suspension leading to pneumonia, severe allergic reactions such as anaphylaxis, bowel obstruction or perforation in patients with existing gastrointestinal lesions, and rare cases of severe constipation that may require medical intervention.

Microtrast should be avoided in patients with known hypersensitivity to barium sulfate, those with recent gastrointestinal surgery, suspected or confirmed bowel perforation, severe constipation, or intestinal obstruction. Caution is also advised for pregnant or lactating women when the diagnostic benefit is not essential.